Cordance Medical
Developing noninvasive focused ultrasound platform to open blood-brain barrier for brain disease treatments.
Website: https://cordancemedical.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Cordance Medical |
| Tagline | Noninvasive focused ultrasound platform to open the blood-brain barrier for brain disease treatments |
| Headquarters | Mountain View, California, United States |
| Founded | 2018 |
| Stage | Seed |
| Business Model | Hardware + Software (medical device) |
| Industry | Healthtech / Medical Devices |
| Technology Type | Hardware (focused ultrasound) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | ~$8,000,000 [PRNewswire, November 2025] |
Links
PUBLIC
- Website: https://cordancemedical.com/
- LinkedIn: https://www.linkedin.com/company/cordance-medical
Executive Summary
PUBLIC
Cordance Medical is a Mountain View-based medical device company developing NeuroAccess, a noninvasive focused ultrasound system designed to transiently open the blood-brain barrier (BBB) so that diagnostics and therapeutics can reach brain tissue that is otherwise pharmacologically unreachable [Cordance Medical, November 2025]. The company was founded in 2018 by Bhaskar Ramamurthy, an ultrasound engineer with prior roles at Acuson, Siemens, Innervision, and SRI International, and is now run day-to-day by CEO Ryan Dittamore, formerly Chief Business Officer of Decipher Biosciences (acquired by Veracyte for $600M) [Cordance Medical; Crunchbase]. NeuroAccess received FDA Breakthrough Device Designation in October 2023 for enabling liquid biopsy in brain tumors using focused ultrasound and microbubbles, a regulatory marker that materially shortens the path to commercialization for the company's first indication [Medical Product Outsourcing, October 2023]. In November 2025, Cordance closed an oversubscribed $8M seed round led by Sonder Capital, with participation from Shanda Grab Ventures, Angel Physician's Fund, SmartGateVC, and R42 [PRNewswire, November 2025]. Preclinical work with EXACT Therapeutics in glioblastoma mouse models reported a 127 to 145 percent increase in radiopharmaceutical uptake when paired with NeuroAccess, an early but specific data point that the platform is enabling rather than merely permeating [PRNewswire, February 2025]. The investable thesis is that Cordance is positioning a hardware platform at the intersection of two large unmet needs (brain tumor diagnostics and CNS drug delivery) where the dominant incumbent, Insightec, is focused primarily on therapeutic ablation rather than BBB opening for biopsy. Over the next 12 to 18 months, watch for sonobiopsy clinical readouts in high-grade glioma, expansion of the EXACT Therapeutics partnership into in-vivo dose escalation, and any partnership announcements with large pharma developing brain-penetrant biologics.
Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, Medical Product Outsourcing, and Crunchbase.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed (closed November 2025) |
| Business Model | Hardware device with software-guided treatment planning |
| Industry / Vertical | Medical devices, neuro-oncology, CNS drug delivery |
| Technology Type | Focused ultrasound + microbubble BBB opening |
| Geography | Headquartered United States; clinical reach North America |
| Growth Profile | Venture scale, regulated medical device timeline |
| Founding Team | Solo founder (Bhaskar Ramamurthy), separate operating CEO |
| Funding | ~$8M total disclosed [PRNewswire, November 2025] |
Company Overview
PUBLIC
Cordance Medical was founded in 2018 by Bhaskar Ramamurthy, PhD, a long-time ultrasound engineer whose prior career at Acuson, Siemens, Innervision, and SRI International centered on diagnostic ultrasound imaging [Focused Ultrasound Foundation; Cordance Medical]. The thesis behind the company is straightforward: focused ultrasound, when paired with intravenous microbubbles, can mechanically and reversibly open the blood-brain barrier in a targeted region of the brain for a window of several hours, allowing molecules that would otherwise be excluded (chemotherapeutics, antibodies, radiopharmaceuticals, or even circulating tumor DNA flowing the other direction into the bloodstream) to cross the barrier [Cordance Medical, Our Solution]. The company is headquartered at 2483 Old Middlefield Way, Suite 120, Mountain View, California [Cordance Medical, Contact].
The most consequential milestone to date is the October 2023 FDA Breakthrough Device Designation for the NeuroAccess platform, granted specifically for enabling liquid biopsy in brain tumors [Medical Product Outsourcing, October 2023; Neurosurgery News International]. That designation followed a first-in-human prospective sonobiopsy trial in high-grade glioma patients using neuronavigation-guided focused ultrasound, the results of which were published in npj Precision Oncology in 2023 [Cordance Medical Publications]. In February 2025, Cordance and Norway-based EXACT Therapeutics announced encouraging preclinical data showing that NeuroAccess increased radiopharmaceutical uptake in glioblastoma mouse models by between 127 and 145 percent versus control [PRNewswire, February 2025; Yahoo Finance, February 2025]. The November 2025 oversubscribed $8M seed financing led by Sonder Capital is the company's first publicly disclosed institutional round and is intended to advance the platform toward clinical milestones [PRNewswire, November 2025].
Despite a 2018 founding, Cordance has operated quietly for most of its life, with the bulk of its public footprint concentrated in the 2023 to 2025 window. That arc (deep technical work behind the scenes, then a regulatory milestone, then a partnership data point, then a seed round) is consistent with a hardware-first medical device company that prioritized de-risking the science before raising visibly priced capital.
Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, Medical Product Outsourcing, and Focused Ultrasound Foundation.
Product and Technology
MIXED
The core product is NeuroAccess, a noninvasive focused ultrasound device designed to temporarily open the blood-brain barrier at a clinician-defined target inside the brain [PUBLIC] [Cordance Medical, Our Solution]. The mechanism, well-established in the focused ultrasound literature, combines low-intensity ultrasound energy with intravenously administered microbubbles; the bubbles oscillate within the targeted vasculature and produce a transient, reversible loosening of the tight junctions in the BBB without thermal ablation [PUBLIC] [Cordance Medical, The Blood-Brain Barrier]. NeuroAccess uses neuronavigation guidance, meaning the treatment is co-registered to the patient's MRI so that the energy can be steered to a specific tumor or anatomical region rather than diffusing across the cortex [PUBLIC] [Cordance Medical Publications].
Two applications anchor the near-term commercial story. The first is sonobiopsy, in which BBB opening is used to release tumor-derived nucleic acids and proteins into the systemic circulation where they can be sampled by a peripheral blood draw, replacing or complementing surgical biopsy in patients where craniotomy carries significant risk [PUBLIC] [Cordance Medical, October 2023]. This is the indication that earned FDA Breakthrough Device Designation in October 2023 [PUBLIC] [Medical Product Outsourcing, October 2023]. The second is enhanced therapeutic delivery, where NeuroAccess opens the BBB immediately before or during dosing of a systemically administered drug so that more of the drug crosses into brain tissue. The EXACT Therapeutics collaboration is the clearest current evidence that this works in vivo, with reported radiopharmaceutical uptake increases of 127 to 145 percent in glioblastoma mouse models [PUBLIC] [PRNewswire, February 2025].
Cordance describes additional disease targets including Alzheimer's, Parkinson's, and epilepsy on its website, framed as future applications rather than active programs [PUBLIC] [Cordance Medical, Homepage]. The technology stack itself is hardware-centric (transducer, control electronics, treatment planning software, MRI co-registration) and the company has not publicly disclosed the manufacturing or supply-chain partners behind the device. Whether NeuroAccess will be sold as a capital equipment purchase, a per-procedure consumable model, or as a service partnered with pharma is not publicly disclosed.
Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, and Medical Product Outsourcing.
Market Research and Opportunity
PUBLIC
The blood-brain barrier is the single biggest reason CNS drug development has historically underperformed oncology and immunology, and any platform that credibly modulates it sits upstream of multiple multi-billion-dollar markets. The barrier excludes roughly 98 percent of small molecules and nearly all large-molecule biologics from the brain parenchyma, which is why decades of investment in Alzheimer's, glioblastoma, and Parkinson's disease have produced relatively few systemically delivered therapies that reach therapeutic concentrations at the target [Cordance Medical, The Blood-Brain Barrier].
No named third-party TAM report for the focused-ultrasound BBB opening market is in the cited research, so we will avoid putting a fabricated dollar figure on the page. What is concrete: glioblastoma alone has roughly 12,000 to 13,000 newly diagnosed US cases per year and a five-year survival rate in the single digits, which is the population the FDA Breakthrough Device Designation directly addresses (analogous market context, widely reported in NCI-published epidemiology). Brain metastases occur in an estimated ten times that volume of cancer patients each year, primarily from lung, breast, and melanoma primaries, and represent a much larger pool of patients who could benefit from either better diagnostic sampling or enhanced drug delivery. Adjacent markets include the radiopharmaceutical category (in which Novartis's Pluvicto and Lutathera have established a commercial template) and the broader CNS biologics pipeline, where every brain-penetrant antibody program is, in effect, a potential combination partner for a BBB-opening platform.
The demand drivers are tangible. Pharma is actively spending on brain-penetrant biologics; Roche, Eli Lilly, and Eisai have all advanced anti-amyloid programs in Alzheimer's that are limited in part by delivery efficiency. Insightec's Exablate Neuro device received FDA approval in 2016 for essential tremor and has subsequently obtained additional indications, demonstrating that focused ultrasound can clear the regulatory bar in brain applications [Insightec public disclosures, widely reported]. Reimbursement pathways for novel medical devices in oncology have improved with CMS pass-through codes for breakthrough-designated products, although coverage is never guaranteed and timelines are long.
| Market signal | Value | Source |
|---|---|---|
| Cordance preclinical uptake increase, glioblastoma mouse model | +127 to +145% | [PRNewswire, February 2025] |
| FDA Breakthrough Device Designation (NeuroAccess, sonobiopsy) | Granted October 2023 | [Medical Product Outsourcing, October 2023] |
| Cordance seed financing | $8M, oversubscribed | [PRNewswire, November 2025] |
The analyst takeaway: there is no published market-sizing report cited in our research that puts a defensible TAM on focused-ultrasound BBB opening, but the convergence of FDA Breakthrough designation, a credible preclinical drug-delivery data point, and the pharma industry's accelerating spend on brain-penetrant biologics together describe a market whose ceiling is set less by addressable patients and more by clinical execution speed.
Data Accuracy: YELLOW -- Cordance-specific data points confirmed by two or more sources; broader TAM context is contextual rather than from a named third-party report.
Competitive Landscape
MIXED
Cordance is positioned as a focused, BBB-opening pure-play in a category where the leading public-company comparable, Insightec, has historically prioritized therapeutic ablation indications over BBB opening for diagnostics and drug delivery.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Cordance Medical | Noninvasive focused ultrasound for BBB opening, lead indication sonobiopsy in brain tumors | Seed, ~$8M total | FDA Breakthrough Device Designation for liquid biopsy enablement | [PRNewswire, November 2025]; [Medical Product Outsourcing, October 2023] |
| Insightec | MR-guided focused ultrasound for brain (essential tremor, Parkinson's tremor, BBB opening research) | Late-stage private, multiple FDA approvals on Exablate Neuro | Installed base of MR-guided systems at major academic centers | [Insightec public disclosures, widely reported] |
The competitive map has three layers. The first is incumbent focused-ultrasound platforms, of which Insightec is the clearest example; its Exablate Neuro system is in clinical use for movement disorders and has been used in investigator-initiated BBB opening studies, including in Alzheimer's and glioblastoma cohorts. The second is the broader BBB-bypass category, which includes intrathecal delivery, convection-enhanced delivery, and engineered antibody shuttles such as those advanced by Denali Therapeutics; these are not direct device competitors but are alternative ways to solve the same delivery problem and will compete for pharma partnership dollars. The third is the diagnostic side: liquid biopsy companies focused on CNS cancers, including efforts at academic centers using cell-free DNA from cerebrospinal fluid, which compete with sonobiopsy on use case rather than on hardware.
Where Cordance has a defensible edge today: the FDA Breakthrough Device Designation is specific to the sonobiopsy indication, which is a use case Insightec has not commercialized, and the team's published first-in-human sonobiopsy data in npj Precision Oncology gives Cordance a clinical and academic head-start in the diagnostic application of BBB opening [Cordance Medical Publications]. The neuronavigation-guided approach (rather than full MR-guided) is potentially lower-cost-per-procedure and easier to deploy outside large academic centers with on-table MR, although that operational advantage has not been quantified in public disclosures. The edge is durable to the extent that Cordance can convert the Breakthrough Designation into a pivotal trial and reimbursement; it is perishable if Insightec or a new entrant pursues sonobiopsy on its installed base.
Where Cordance is most exposed: Insightec already has revenue, an installed base at top academic neurosurgery centers, and existing relationships with the neurosurgeons who would be early adopters of any BBB platform. If a large pharma signs a brain-penetrant drug-delivery partnership with Insightec, the channel implications would be significant. Cordance is also a small team competing for the same pharma business development conversations as much larger players in CNS delivery.
The most plausible 18-month scenario: winner if Cordance reads out positive sonobiopsy clinical data in high-grade glioma and converts the EXACT Therapeutics partnership into a second, named pharma collaboration on a brain-penetrant therapeutic. Loser if Insightec announces a competing sonobiopsy program on its Exablate platform before Cordance enters its pivotal trial, in which case Cordance's regulatory head-start narrows and channel disadvantage widens.
Data Accuracy: YELLOW -- Cordance positioning confirmed by multiple cited sources; competitor positioning sourced from public disclosures rather than direct comparison data.
Opportunity
PUBLIC
If NeuroAccess works as advertised at clinical scale, Cordance is not a single-product device company; it is the enabling layer for an entire generation of brain-penetrant therapeutics and diagnostics.
The headline opportunity is to become the default hardware platform that pharma partners with whenever a CNS drug needs help crossing the blood-brain barrier. That is a platform position rather than a product position, and the cited evidence makes it reachable rather than aspirational: the FDA Breakthrough Device Designation establishes regulatory credibility for the sonobiopsy use case [Medical Product Outsourcing, October 2023], the EXACT Therapeutics preclinical data demonstrates the platform meaningfully boosts drug uptake in glioblastoma models [PRNewswire, February 2025], and the published first-in-human sonobiopsy work signals that the company can move from animal model to patient with a coherent clinical protocol [Cordance Medical Publications]. Three independent vectors (regulatory, pharma partnership, clinical publication) are pointing in the same direction at the seed stage, which is uncommon.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Sonobiopsy standard of care | NeuroAccess becomes the routine alternative to surgical biopsy in inoperable brain tumors | Pivotal sonobiopsy trial readout in high-grade glioma | FDA Breakthrough Designation already granted [Medical Product Outsourcing, October 2023] |
| Pharma delivery platform | Multiple pharma partners license NeuroAccess as the BBB-opening companion to brain-penetrant biologics and radiopharmaceuticals | Second named pharma partnership beyond EXACT Therapeutics | EXACT collaboration showed +127 to +145% uptake in GBM models [PRNewswire, February 2025] |
| Indication expansion | Platform extends from oncology into Alzheimer's and Parkinson's drug delivery | Investigator-initiated trials in neurodegenerative disease | Company explicitly cites these as target indications [Cordance Medical, Homepage] |
The compounding mechanic is a partnership flywheel rather than a network effect in the consumer sense. Each pharma partner that signs a co-development or supply agreement validates the platform for the next conversation, and each clinical readout (Cordance's own or an investigator-initiated study using its hardware) generates published evidence that lowers the diligence cost for the following partner. The EXACT Therapeutics collaboration is the first visible turn of that flywheel [PRNewswire, February 2025]. On the diagnostic side, every sonobiopsy procedure produces clinical data that strengthens the regulatory and reimbursement case for the next center to adopt.
For the size of the win: comparable framing rather than forecast. Decipher Biosciences, where current Cordance CEO Ryan Dittamore previously served as CBO, was acquired by Veracyte for $600M, illustrating what a focused, evidence-driven oncology diagnostics company can be worth at exit [Cordance Medical]. Insightec has reportedly been valued in the multiple-billions in private financings, illustrating what a focused-ultrasound platform with broad CNS indications can command. Neither is a forecast for Cordance, but both bracket the range of plausible outcomes if execution holds (scenario, not a forecast). The downside framing belongs in the private half of this report.
Data Accuracy: GREEN -- Confirmed by PRNewswire, Medical Product Outsourcing, and Cordance Medical primary sources.
Sources
PUBLIC
[Cordance Medical] Cordance Medical Homepage | https://cordancemedical.com/
[Cordance Medical] Our Solution | https://cordancemedical.com/our-solution/
[Cordance Medical] Team Members - Bhaskar Ramamurthy | https://cordancemedical.com/team-members/
[Cordance Medical] Eric Leuthardt, MD profile | https://cordancemedical.com/team-members/eric-leuthardt-md/
[Cordance Medical] The Blood-Brain Barrier | https://cordancemedical.com/the-problem/blood-brain-barrier/
[Cordance Medical] Brain Cancers | https://cordancemedical.com/the-problem/cancer/
[Cordance Medical] Contact Us | https://cordancemedical.com/contact-us/
[Cordance Medical, October 2023] NeuroAccess Receives FDA Breakthrough Device Designation for Liquid Biopsy in Brain Tumors | https://cordancemedical.com/cordance-medicals-neuroaccess-receives-fda-breakthrough-device-designation-for-liquid-biopsy-in-brain-tumors/
[Cordance Medical, November 2025] $8M Seed Financing Announcement | https://cordancemedical.com/cordance-medical-announces-an-oversubscribed-8m-seed-financing-to-advance-focused-ultrasound-platform-for-brain-disease-treatment/
[PRNewswire, November 2025] Cordance Medical Announces an Oversubscribed $8M Seed Financing | https://www.prnewswire.com/news-releases/cordance-medical-announces-an-oversubscribed-8m-seed-financing-to-advance-focused-ultrasound-platform-for-brain-disease-treatment-302624669.html
[PRNewswire, February 2025] Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model | https://finance.yahoo.com/news/cordance-medical-exact-therapeutics-announce-183600610.html
[Medical Product Outsourcing, October 2023] Cordance's Blood-Brain Barrier Opening Device Wins FDA Breakthrough Nod | https://www.mpo-mag.com/contents/view_breaking-news/2023-10-30/cordances-blood-brain-barrier-opening-device-wins-fda-breakthrough-nod
[Neurosurgery News International] Cordance gains US FDA breakthrough designation for NeuroAccess technology | https://neuronewsinternational.com/cordance-gains-us-fda-breakthrough-designation-for-neuroaccess-technology/
[Focused Ultrasound Foundation] Company Profile: Cordance Medical | https://www.fusfoundation.org/posts/company-profile-cordance-medical/
[Focused Ultrasound Foundation] FDA Grants Breakthrough Device Designation for Cordance Medical's Brain Tumor Liquid Biopsy Platform | https://www.fusfoundation.org/posts/fda-grants-breakthrough-device-designation-for-cordance-medicals-brain-tumor-liquid-biopsy-platform/
[Surgical Robotics Technology] Cordance Medical Reports an Oversubscribed $8M Seed Financing | https://www.surgicalroboticstechnology.com/news/cordance-medical-reports-an-oversubscribed-8m-seed-financing/
[Crunchbase] Cordance Medical company profile | https://www.crunchbase.com/organization/cordance-medical
[Crunchbase] Ryan Dittamore profile | https://www.crunchbase.com/person/ryan-dittamore
[Crunchbase] Bhaskar Ramamurthy profile | https://www.crunchbase.com/person/bhaskar-ramamurthy-8082
[PitchBook] Cordance Medical 2026 Company Profile | https://pitchbook.com/profiles/company/437326-84
[Tracxn] Cordance Medical company profile | https://tracxn.com/d/companies/cordance-medical/__k_3a5s9ez-Y-JeOF-IhCsFnr4NrBvvGF6yssQqGEmKA
[LinkedIn] Cordance Medical company page | https://www.linkedin.com/company/cordance-medical
Articles about Cordance Medical
- Cordance Medical Wants a Focused Ultrasound Beam to Pry Open the Blood-Brain Barrier — The Mountain View startup raised $8M to push its NeuroAccess device into trials for glioblastoma patients who today have almost no good options.